<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654612</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaIMF-LP02</org_study_id>
    <nct_id>NCT03654612</nct_id>
  </id_info>
  <brief_title>Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies</brief_title>
  <acronym>Y-HR2017-025</acronym>
  <official_title>A Single Arm,Open Clinical Study of Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China International Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Society of Clinical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China International Medical Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in
      combination with S-1 as second-line treatment of advanced head and neck malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>40 months</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>40 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib+S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle</description>
    <arm_group_label>Apatinib+S-1</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old, male or female;

          2. Pathologically diagnosed advanced head and neck malignant tumors with measurable
             lesions (spiral CT scan ≥10mm, meeting RECIST 1.1 criteria);

          3. Late, recurrent or metastatic malignant tumors of the head and neck that are
             inoperable and radiotherapy;

          4. According to CTCAE 4.0 and the patient's complaint, the investigator judged patients
             who were intolerable by second-line combined chemotherapy;

          5. ECOG PS: 0-1 points;

          6. Baseline blood and biochemical indicators meet the following criteria:

             Hemoglobin ≥ 80g/L, Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥ 90×109/L,
             ALT, AST ≤ 2.5 times the normal upper limit, ≤ 5 times the normal upper limit (with
             liver metastases), Serum total bilirubin ≤ 1.5 times the normal upper limit, Serum
             creatinine ≤ 1.5 times the normal upper limit, Serum albumin ≥ 30g / L;

          7. The expected survival period is ≥3 months;

          8. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days
             prior to enrollment and the results are negative, and are willing to use appropriate
             methods of contraception during the trial and 8 weeks after the last administration of
             the test drug. For men, surgery should be sterilized, or consent should be used during
             the trial and 8 weeks after the last administration of the test drug.

          9. Subjects volunteered to participate in the study, signed informed consent, and were
             well-adhered to follow-up.

        Exclusion Criteria:

          1. A person who has been confirmed to be allergic to apatinib and/or its excipients;

          2. Patients with hypertension and antihypertensive medication can not be reduced to
             normal range (systolic blood pressure &gt;140 mmHg, diastolic blood pressure &gt;90 mmHg),
             with grade I or higher coronary heart disease, grade I arrhythmia (including QTc
             interval prolongation) Male &gt; 450 ms, female &gt; 470 ms) and grade I cardiac
             insufficiency; urine protein positive patients;

          3. Have multiple factors affecting oral medications (such as inability to swallow,
             nausea, vomiting, chronic diarrhea, and intestinal obstruction);

          4. Patients who have used apatinib or tigeo in the first line

          5. abnormal blood coagulation (INR&gt;1.5, APTT&gt;1.5 ULN), with bleeding tendency;

          6. Patients with central nervous system metastases;

          7. Pregnant or lactating women;

          8. Patients with other malignancies within 5 years;

          9. Patients with a history of psychotropic substance abuse who are unable to quit or have
             a mental disorder;

         10. Patients who have participated in other drug clinical trials within 4 weeks;

         11. Have received VEGFR inhibitors such as sorafenib and sunitinib;

         12. According to the investigator's judgment, there are serious patients who are at risk
             to the patient's safety or affect the patient's accompanying disease to complete the
             study;

         13. The investigator believes that it is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu Ping, doctor</last_name>
    <phone>13975157508</phone>
    <email>CYRIL0820@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu Bin, doctor</last_name>
    <phone>13973127325</phone>
    <email>Binglang3351@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Second Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ping liu</last_name>
      <phone>(+86)13975157508</phone>
      <email>cyril0820@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China International Medical Foundation</investigator_affiliation>
    <investigator_full_name>Ping Liu</investigator_full_name>
    <investigator_title>Attending doctor in oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

